GenSight Biologics Provides Updates about GS010/LUMEVOQ® Early Access Programs and the Ongoing REVISE Study

Core Viewpoint - GenSight Biologics is advancing its gene therapy candidate GS010/LUMEVOQ® for retinal neurodegenerative diseases and central nervous system disorders, with updates on early access programs and a dose-ranging study [1] Group 1: Company Updates - GenSight Biologics provided updates on the GS010/LUMEVOQ® early access programs currently underway [1] - The company is conducting an ongoing dose-ranging study named REVISE for GS010/LUMEVOQ® [1] - GS010/LUMEVOQ® is positioned as a candidate gene therapy in clinical development [1]